Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions

Edesa Biotech Inc EDSA has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized COVID-19 patients.
Related: Edesa Biotech Provides Update For COVID-19 Antibody Trial.
Overall, EB05 + Standard of Care treatment (SOC) reduced mortality risk by 68.5% compared to placebo + SOC at 28 days.
Among the findings, the DSMB noted another mortality benefit in 136 hospitalized COVID-19 patients receiving supplemental oxygen (28-day mortality rate of 8.2% in the EB05 + SOC arm versus 12.0% in the placebo + SOC arm).
Confirmatory efficacy signals were detected in other groups, including the 190 patients with mild to moderate ARDS at baseline (28-day mortality rate of 7.8% in the EB05 + SOC arm versus 11.0% in the placebo + SOC arm).
Within this group, patients demonstrated a 50.7% reduction in the risk of dying in the EB05 + SOC arm compared to placebo + SOC.
Related: Edesa Biotech Stock Is Rallying After COVID-19 Antibody Data: What You Need To Know.
Price Action: EDSA shares are up 5.36% at $8.16 during the market session on the last check Tuesday.